Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Bolt Biotherapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 66 | 2 | 62 | −2 |
| Shares | 29.0M | 20.8K | 26.8M | −2.20M (−7.6%) |
| Value | $79.3M | $58.0K | $54.8M | −$24.4M (−30.9%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Newtyn Management, LLC | 748,252 | $1.53M | 0.29% |
| Ra Capital Management, L.P. | 450,141 | $918.0K | 0.02% |
| Assenagon Asset Management S.A. | 275,552 | $562.0K | 0.00% |
| Tang Capital Management LLC | 200,000 | $408.0K | 0.06% |
| Millennium Management LLC | 191,856 | $391.0K | 0.00% |
| Oasis Management Co Ltd. | 107,500 | $219.0K | 0.04% |
| Ergoteles LLC | 105,655 | $216.0K | 0.01% |
| Russell Investments Group, Ltd. | 96,100 | $196.0K | 0.00% |
| Marquette Asset Management, LLC | 63,779 | $130.0K | 0.04% |
| Eversept Partners, LP | 31,172 | $63.6K | 0.01% |
| Two Sigma Advisers, LP | 26,300 | $54.0K | 0.00% |
| Man Group plc | – | $37.0K | 0.00% |
| Susquehanna International Group, LLP | 17,535 | $36.0K | 0.00% |
| Prudential Financial Inc | 16,200 | $33.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 14,612 | $30.0K | 0.00% |
| Prelude Capital Management, LLC | 10,994 | $22.0K | 0.00% |
| Capital Advisors, Ltd. LLC | 106 | $0 | 0.00% |
Sold out (19)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Holocene Advisors, LP | 1,164,927 | $3.19M |
| Eventide Asset Management, LLC | 859,826 | $2.36M |
| Armistice Capital, LLC | 400,000 | $1.10M |
| Nuveen Asset Management, LLC | 75,286 | $221.0K |
| Charles Schwab Investment Management Inc | 50,856 | $140.0K |
| Swiss National Bank | 28,000 | $77.0K |
| Deutsche Bank AG | 24,422 | $67.0K |
| Rhumbline Advisers | 23,651 | $65.0K |
| California State Teachers Retirement System | 21,048 | $58.0K |
| Ensign Peak Advisors, Inc | 18,500 | $51.0K |
| JustInvest LLC | 17,883 | $49.0K |
| PDT Partners, LLC | 12,219 | $33.0K |
| American International Group, Inc. | 11,363 | $31.0K |
| Prospera Financial Services Inc | 4,208 | $12.0K |
| Amalgamated Bank | 2,755 | $8.00K |
| Nisa Investment Advisors, LLC | 3,100 | $8.00K |
| Ameritas Investment Partners, Inc. | 1,754 | $5.00K |
| Toronto Dominion Bank | 3 | $0 |
| Echo Street Capital Management LLC | 123,804 | – |
Not filed for Q2 2022 yet (2)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 18,082 | $50.0K |
| Amalgamated Financial Corp. | 2,755 | $8.00K |